For each trial, check who or what was studied, which preparation was used and what the findings support before comparing it with personal reports about individual experiences or seller listings that describe a product but don’t establish that it works.
Regulatory context
Regulatory context; not efficacy evidence
No matched controlled clinical study of the exact no-DAC stock was verified in this audit.
Reported findings. Background context only. Matched evidence for the exact marketed formulation is not established by this reference.
Nonresponse. Nonresponse frequency not established in this excerpt.
Harms. Unknown in reviewed excerpt; absence of mention is not safety evidence.
Limits. Do not transfer the multi-day pharmacokinetics of CJC-1295 with DAC to Modified GRF 1-29.
Preparation: Source preparation; commercial equivalence unverified. Route: Unknown in reviewed excerpt; do not infer.
Read original source ↗Editorial review 2026-10-09. Clinician review pending.
Human report
Public no-DAC CJC1295 plus ipamorelin firsthand report
One public firsthand account; identity and clinical outcomes unverified.
Reported findings. During eight weeks of combined no-DAC CJC1295 and ipamorelin use, the author reports strength changes beginning around week four, with 5-10 lb bench/squat increases every other week, less next-day soreness and more tracker-estimated deep sleep. Slight visual body-composition changes were also reported.
Nonresponse. No formal nonresponse endpoint reported. Body-composition changes were described as modest and qualitative; the original report supplies no numerical body-composition or hormone results.
Harms. A head flush or tingling lasting about ten minutes after injection and vivid dreams were reported. The author did not describe strong hunger spikes; this does not establish their absence in other people.
Limits. Combined ipamorelin exposure, training and fasting prevent allocating changes to CJC1295 alone. No-DAC identity is named by the author; findings do not transfer to CJC1295 with DAC. Strength increments are self-reported, not independently checked training logs; tracker-estimated deep sleep is not polysomnography, and visual body composition is not measured fat loss. The post displays a deleted author account while its body remains visible. Adjacent comments, including other deleted accounts, are not automatically the same author or additional independently verified outcomes. Subjective reports supply neither causal proof nor a population response rate. Exact original publication/edit dates and preparation chemistry remain unknown. Browser rendering may be cached and the original-URL raw request returned HTTP 403.
Preparation: Named no-DAC CJC1295 plus ipamorelin; chemistry and brand unspecified. Route: Injection described; intramuscular versus subcutaneous route unspecified.
Read original source ↗Editorial review 2026-10-15. Clinician review pending.
Human report
Public no-DAC CJC1295 plus ipamorelin adverse experience
One public firsthand account; the same visible commenter separately reports existing cardiology care. No diagnosis, measurements or clinical records verified.
Reported findings. No beneficial outcome described by this commenter. Other people's adjacent positive replies are not this author's outcome.
Nonresponse. Only two exposures were reported before the uncomfortable heart-rate rise. A benefit endpoint, formal nonresponse assessment and later course were not established.
Harms. The commenter reports resting heart rate rising beyond their comfort level; no numerical rate, ECG findings or diagnosed arrhythmia were supplied. A same-author reply says they already see a cardiologist, without stating a diagnosis.
Limits. Combined exposure prevents attribution to CJC1295 alone. Existing cardiology care is relevant self-reported context, not a verified diagnosis or a causal explanation. The adverse comment does not specify an administration route; the other report's injection route cannot be inherited. No-DAC and DAC formulations remain separate. The same-author cardiology reply is a substantive supporting source, not an additional independent report. Nearby replies about other compounds or other people are not assigned to this account. Self-selection, incomplete cardiovascular context and unverified preparation/clinical records prevent population harm estimates or proof of causation. Parent/comment timestamps remain unknown. Primary rendering may be cached; one raw primary-URL request returned HTTP 403. Supporting-reply raw retrieval was not attempted.
Preparation: Named no-DAC CJC1295 plus ipamorelin; chemistry and brand unspecified. Route: Not specified by this commenter.
Read original source ↗Editorial review 2026-10-15. Clinician review pending.